Digital Obesity Care Reaches All Income Groups – But Financial Barriers Create Health Inequalities
New real-world data from over 40,000 patients show that digital obesity care produces significant and sustained weight loss even with low medication doses.
UK firms eye GLP-1 benefits to cut sick leave and boost performance.
UK employers are increasingly considering weight-loss support as part of employee benefits, as new Yazen patient data links GLP-1 treatment to reduced sick days and improved workplace performance.
Yazen Highly Commended in the HTN Now 2025/26 Awards
Yazen’s work powering digital patient transformation for sustainable weight care is recognised by the HTN Now 2025/26 Awards in the category of Digital Patient Transformation.
WHO says obesity is a chronic, relapsing disease needing lifelong care
The WHO released its first global guideline for GLP-1 obesity treatment, recognizing obesity as a chronic disease. Long-term care combined with therapy is key.
Sifted UK: Yazen raises €19.5m to expand obesity treatment in the EU
Yazen has secured €19.5 million in Series A funding to expand its GLP-1-based obesity treatment across Europe. The company combines medication with lifestyle support for sustainable weight loss results.
Startups shifting to GLP-1s to tap into $150bn weight loss market
GLP-1 weight loss drugs like Wegovy are attracting startups and investors, aiming to tap into the projected $150bn market despite supply and reimbursement challenges
Join Health Tech World's webinar with experts discussing sustainable weight loss through medication, lifestyle changes, and digital health tools. Watch now!
.webp)
